VitiligoWeb.com
Here is an interesting study that found differences in Vitiligo patterns between people in India and the UK.
Indian patients with vitiligo have several striking differences in the pattern of their disease from patients with European heritage, a UK and Indian research team have discovered.
Interestingly, the presence of antibodies was significantly more likely in patients without a family history of vitiligo or other autoimmune disorders than those with these factors, the team notes.
Patients with non-segmental vitiligo were also more likely to have antibodies than those with the segmental form (50-60% vs 0-17%).
to read the full article, click here:
http://www.medwire-news.md/66/96297/Dermatology/Indian_vitiligo_patients_disease_pattern_differs_from_Europeans.html
-----
Thursday, December 15, 2011
Sunday, December 4, 2011
Another company with Vitiligo drug in trials
VitiligoWeb.com
Here is another company I just read about that has a drug for Vitiligo in trials. It is a drug to help tanning in a rare form of skin disease, but it also may have applications for Vitiligo. The company is in Australia and is called Clinuvel Pharmaceuticals Ltd. The drug is called Scenesse.
Scenesse's initial market comprises only about 10,000 patients, but it has the potential for treating millions more. The drug is in mid-stage testing for treating vitiligo, which causes some blacks and Hispanics to lose skin pigmentation and results in unsightly white skin blotches. The disease affects an estimated 40 million people in the developed world.
He insists U.S. regulators would never approve Scenesse for tanning rather than a medical condition. He noted that once a drug is approved for one use, it is easier to gain additional, potentially more lucrative, approvals, such as for vitiligo.
Link to full article:
http://www.trust.org/alertnet/news/interview-tiny-clinuvel-spurns-tanning-for-medical-need
-----
Here is another company I just read about that has a drug for Vitiligo in trials. It is a drug to help tanning in a rare form of skin disease, but it also may have applications for Vitiligo. The company is in Australia and is called Clinuvel Pharmaceuticals Ltd. The drug is called Scenesse.
Scenesse's initial market comprises only about 10,000 patients, but it has the potential for treating millions more. The drug is in mid-stage testing for treating vitiligo, which causes some blacks and Hispanics to lose skin pigmentation and results in unsightly white skin blotches. The disease affects an estimated 40 million people in the developed world.
He insists U.S. regulators would never approve Scenesse for tanning rather than a medical condition. He noted that once a drug is approved for one use, it is easier to gain additional, potentially more lucrative, approvals, such as for vitiligo.
Link to full article:
http://www.trust.org/alertnet/news/interview-tiny-clinuvel-spurns-tanning-for-medical-need
-----
Subscribe to:
Posts (Atom)